DiagnosticImaging Members: Login | Register
Diagnostic Imaging Recommended Medical Sites Medline Drugs

Powered by SearchMedica

 
  • Home
  • Blog
  • Conference Reports
  • Case Studies
  • Jobs
  • Product Directory
  • Voice Recognition
  • Low Dose
  • RSNA 2011
  • PET-MR

Home » Daily News

 

Nuclear studies show benefits of progenitor cell therapy

James Brice
April 11, 2008

German researchers have demonstrated the value of PET and SPECT imaging for monitoring the ability of circulating progenitor cells injected in the coronary arteries to preserve the integrity of myocardial tissue following recanalization.

Twenty-six patients with occlusive coronary artery disease took part in the randomized placebo-controlled double-blinded study. FDG-PET and technetium-99m tetrofosmine-SPECT were performed about eight days after coronary interventions to image relative changes in myocardial perfusion and glucose metabolism. Segments were classified as normal, perfusion-metabolism mismatch, or scar.

After another two days, patients were randomly selected to receive either repeated intracoronary infusions of progenitor cells (69±14x106 CPC) in the recanalized vessel or the same procedure with placebo serum. Cells had previously been harvested from the patients' venous blood and cultured ex vivo in an endothelial-specific medium.

FDG-PET and SPECT imaging repeated three months later found a significant decline in the number of segments of myocardial perfusion-metabolism mismatch among patients who received the progenitor cell infusion compared with controls.

In the CPC group, 48.5% of the segments diplaying a perfusion-metabolism mismatch on baseline scans were normal on follow-up studies. About 9% turned into scar, and 42.4% remained a mismatch. Among patients receiving a placebo, 12.5% of the segments normalized, 20.8% evolved into scar, and 66.7% retained a perfusion-metabolism mismatch.

The study was published in the April issue of the Journal of Nuclear Medicine (2008;49:557-563)

PET and SPECT were uniquely capable of measuring the physiological response to the progenitor cell infusion, said first author Dr. Kai Kendziorra, a nuclear medicine specialist at the University of Leipzig.

"The results shown by these imaging modalities provide the evidence needed to expand the use of CPC treatment." he said in a release from the Society of Nuclear Medicine.

Earlier research had shown that when a patient's progenitor cells are activated by growth factors, the result is increased cell division, which is vital to the tissue repair process. In this study, progenitor cells developed from circulating blood were also found to be capable of repairing hibernating myocardium.

Kendziorra noted that PET and SPECT may also play a role before coronary interventions to help select patients who would benefit from CPC administration.

"Early detection of hibernating myocardial tissue via noninvasive imaging modalities such as PET and SPECT will help us to assess a patient's myocardial metabolism and blood flow," he said. "Subsequent early coronary recanalization and CPC administration may lead to treatment-specific normalization and reduce the risk of cardiac events over longer periods."

For more information from the Diagnostic Imaging archives:

Nuclear medicine embraces MI applications

Labeling studies follow human stem cell therapies

MI tracks stem cell delivery and uptake

 

Join the Conversation

Want to join the conversation? Just sign in or register today to become part of our growing, online community.






TopicIndex

 

ACOs
Cardiac
Case Studies
Colonography
CT
Digital X-ray
Direct Radiography
Elastography
Low-Dose Modalities
Meaningful Use
Molecular Imaging
MRI
 

 

Nuclear
PACS
PET/CT
PET/MR
Practice Management
RIS
Teleradiology
Ultrasound Imaging
Vendors
Voice Recognition
Women's Imaging
All Topics
 


SponsoredResources


OptumInsight
Acadiana Computer Systems, Inc. gains a 100% ROI on their radiology billing


Key Equipment Finance
Michiana Hematology Oncology Success Story


Barco
Multi-modality breast imaging using RapidFrame™ technology


Siemens
3D Ultrasound of the Breast


Ziosoft, Inc.
PhyZiodynamic Solutions: Applying Supercomputing to Patient Care


Siemens
Easy Guide to Low Dose


Medrad
Improving Clinical Outcomes and Workflow
Toshiba America Medical Systems
Minimizing dose, sedation in pediatric CT

 

View All

 


  • On This Site
  • Most Emailed
  • On This Topic

MostPopular

  • Whole-breast ultrasound brings significant screening benefits

    JAN 15 2010 DIAGNOSTIC IMAGING ASIA PACIFIC READ >>

  • CNN Investigation Targets Radiology Board Exam Cheating

    JAN 13 2012 READ >>

  • As teleradiology evolves, it changes dramatically, plays growing role in practice

    DEC 15 2010 DIAGNOSTIC IMAGING READ >>

  • Delayed side effects persist in IV iodinated contrast media

    MAY 28 2009 DIAGNOSTIC IMAGING EUROPE READ >>

  • Mucinous Adenocarcinoma of Stomach

    JAN 9 2012 READ >>

MostPopular

  • CNN Investigation Targets Radiology Board Exam Cheating

    JAN 13 2012 READ >>

  • Telemammography Taking Hold

    JAN 24 2012 READ >>

  • Riverain’s Chest X-Ray Comparison Tool Gets FDA Nod

    JAN 11 2012 READ >>

  • Podcast: Implementing a Hybrid PET/MR System

    JAN 30 2012 READ >>

  • Taking Medical Image Sharing to the Cloud

    JAN 19 2012 READ >>

MostPopular

  • CNN Investigation Targets Radiology Board Exam Cheating

    JAN 13 2012 READ >>

  • Radiology Comic: Doctors Cheating

    JAN 31 2012 READ >>

  • CNN Look at Radiology Exam "Cheating" Misses the Mark

    JAN 24 2012 READ >>

  • Columbus Radiology Launches Imaging Ordering App

    JAN 19 2012 READ >>

  • Radiology Comic: Bad Apple

    JAN 17 2012 READ >>



CancerNetwork | CME LLC | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2012 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy